HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gribble, F. M. Articles by Levy, J. C. Search for Related Content PubMed PubMed Citation Articles by Gribble, F. M. Articles by Levy, J. C. Social Bookmarking                What's this?

Randomized Dose Ranging Study of the Reduction of Fasting and Postprandial Glucose in Type 2 Diabetes by Nateglinide (A-4166)

¹ Department of Clinical Biochemistry, Addenbrooke’s Hospital, Cambridge
² Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, U.K.

OBJECTIVE—This randomized crossover double-blind placebo-controlled study aimed to assess the efficacy of nateglinide (A-4166), a novel phenylalanine-derived insulin secretagogue, in type 2 diabetic subjects while fasting and 5 min before a standard meal.

RESEARCH DESIGN AND METHODS—A single dose of nateglinide (60, 120, or 180 mg) or placebo was given to eight diet-treated overnight-fasted type 2 diabetic patients and to seven patients 5 min before a standard breakfast. Plasma glucose, radioimmunoassay insulin, and nateglinide were measured at baseline and for a further 180 min.

RESULTS—The time-averaged 180-min postdose mean decrease in fasting plasma glucose concentration was greater after nateglinide (1.8 mmol/l; 95% CI 1.5–2.0) than after placebo (0.7 mmol/l; 95% CI 0.3–1.2) (P < 0.001). Hypoglycemia did not develop in any of the subjects. Insulin concentrations increased 1.5-, 1.8-, and 1.9-fold with the 60-, 120-, and 180-mg doses, respectively (P < 0.001), peaking 30 min after the dose. Nateglinide concentrations peaked after 30 min, decreasing to 21% of peak by 180 min. In the meal test, the mean increase (2.9 mmol/l, 2.3–3.6) in plasma glucose over 180 min after placebo was reduced by 1.8 mmol/l (P < 0.001) with the two higher doses of nateglinide.

CONCLUSIONS—A single dose of nateglinide administered to diet-treated type 2 diabetic patients with fasting hyperglycemia increased insulin secretion and reduced fasting glucose without hypoglycemia. Administered 5 min before a meal, nateglinide reduced the postprandial glucose excursion by 64%. With its rapid onset and short duration of action, nateglinide is a promising oral prandial therapy in type 2 diabetes.

Abbreviations: K_ATP, ATP-sensitive K⁺ channel • UKPDS, U.K. Prospective Diabetes Study

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. H Frid, M. Nilsson, J. J. Holst, and I. M. Bjorck Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects Am. J. Clinical Nutrition, July 1, 2005; 82(1): 69 - 75. [Abstract] [Full Text] [PDF]

				J. Davidson Should Postprandial Glucose Be Measured and Treated to a Particular Target? Yes. Diabetes Care, June 1, 2003; 26(6): 1919 - 1921. [Full Text] [PDF]

				M. Chachin, M. Yamada, A. Fujita, T. Matsuoka, K. Matsushita, and Y. Kurachi Nateglinide, a D-Phenylalanine Derivative Lacking Either a Sulfonylurea or Benzamido Moiety, Specifically Inhibits Pancreatic beta -Cell-Type KATP Channels J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1025 - 1032. [Abstract] [Full Text] [PDF]

				C. A Reasner and B. Goke Overcoming the barriers to effective glycaemic control for type 2 diabetes The British Journal of Diabetes & Vascular Disease, July 1, 2002; 2(4): 290 - 295. [PDF]

				C. G. Parkin and N. Brooks Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings? Clin. Diabetes, April 1, 2002; 20(2): 71 - 76. [Abstract] [Full Text] [PDF]